Triple combination therapies for anti-aging
US-2024316086-A1 · Sep 26, 2024 · US
Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells
US9273317B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9273317-B2 |
| Application number | US-201214237838-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 9, 2012 |
| Priority date | Aug 9, 2011 |
| Publication date | Mar 1, 2016 |
| Grant date | Mar 1, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inhibiting the growth and/or proliferation of a neuroblastoma tumor cell having increased expression of a Myc transcription factor as compared to a non-tumor cell of the same cell type, comprising the step of contacting the tumor cell with at least one inhibitor that inhibits the gene product of at least one of the following genes: PES1, TIE1, or CECR2, wherein the inhibitor interferes with production or expression of the gene product of the gene. 2. The method of claim 1 , wherein the tumor cell is a metastatic neuroblastoma tumor. 3. The method of claim 1 , wherein the tumor cell is contacted in vitro. 4. The method of claim 1 , wherein the tumor cell is contacted in vivo in a mammalian subject. 5. A method of treating a subject suffering from a neuroblastoma tumor having increased expression of a Myc transcription factor as compared to a non-tumor cell of the same cell type, comprising administering to the subject an amount of a composition comprising an inhibitor that inhibits the gene function of at least one of the following genes: PES1, TIE1, or CECR2, and is effective to inhibit the growth and/or proliferation of the tumor, wherein the inhibitor interferes with production or expression of the gene product of the gene. 6. The method of claim 1 wherein the gene is CECR2. 7. The method of claim 1 wherein the gene is PES1. 8. The method of claim 1 wherein the gene is TIE1. 9. The method of claim 5 wherein the gene is CECR2. 10. The method of claim 5 wherein the gene is PES1. 11. The method of claim 5 wherein the gene is TIE1. 12. The method of claim 5 wherein the tumor is a metastatic neuroblastoma tumor. 13. A method for inhibiting the growth and/or proliferation of an ovarian tumor cell having increased expression of a Myc transcription factor as compared to a non-tumor cell of the same cell type, comprising the step of contacting the tumor cell with at least one inhibitor that inhibits the gene product of at least one of the following genes: PES1, TIE1, CRKRS or CECR2, wherein the inhibitor interferes with production or expression of the gene product of the gene. 14. The method of claim 13 , wherein the tumor cell is contacted in vitro. 15. The method of claim 13 , wherein the tumor cell is contacted in vivo in a mammalian subject. 16. The method of claim 13 wherein the gene is CRKRS. 17. The method of claim 13 wherein the gene is CECR2. 18. The method of claim 13 wherein the gene is PES1. 19. The method of claim 13 wherein the gene is TIE1. 20. A method of treating a subject suffering from an ovarian tumor having increased expression of a Myc transcription factor as compared to a non-tumor cell of the same cell type, comprising administering to the subject an amount of a composition comprising an inhibitor that inhibits the gene function of at least one of the following genes: PES1, TIE1, CRKRS or CECR2, and is effective to inhibit the growth and/or proliferation of the tumor, wherein the inhibitor interferes with production or expression of the gene product of the gene. 21. The method of claim 20 wherein the gene is CRKRS. 22. The method of claim 20 wherein the gene is CECR2. 23. The method of claim 20 wherein the gene is PES1. 24. The method of claim 20 wherein the gene is TIE1.
Assignees
Inventors
Classifications
interfering nucleic acids [NA] · CPC title
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
- A61K31/65Primary
Tetracyclines · CPC title
Indoles, e.g. pindolol · CPC title
Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9273317B2 cover?
- The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells.
- Who is the assignee on this patent?
- Toyoshima Masafumi, Grandori Carla, Hutchinson Fred Cancer Res
- What technology area does this patent fall under?
- Primary CPC classification A61K31/65. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).